Ursula Thyroff‐Friesinger

538 total citations
28 papers, 440 citations indexed

About

Ursula Thyroff‐Friesinger is a scholar working on Pediatrics, Perinatology and Child Health, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Ursula Thyroff‐Friesinger has authored 28 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pediatrics, Perinatology and Child Health, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Pharmacology. Recurrent topics in Ursula Thyroff‐Friesinger's work include Erythropoietin and Anemia Treatment (5 papers), Biosimilars and Bioanalytical Methods (5 papers) and Antibiotics Pharmacokinetics and Efficacy (5 papers). Ursula Thyroff‐Friesinger is often cited by papers focused on Erythropoietin and Anemia Treatment (5 papers), Biosimilars and Bioanalytical Methods (5 papers) and Antibiotics Pharmacokinetics and Efficacy (5 papers). Ursula Thyroff‐Friesinger collaborates with scholars based in Germany, Austria and United States. Ursula Thyroff‐Friesinger's co-authors include Kurt G. Naber, Marianne Haag–Weber, Martina Kinzig, K. Weigang-Köhler, Fritz Sörgel, Markus Müller, Hartmut Derendorf, P.-A. Fischer, Joachim Bargon and Rossen Koytchev and has published in prestigious journals such as SHILAP Revista de lepidopterología, Pharmaceutical Research and Pharmacological Research.

In The Last Decade

Ursula Thyroff‐Friesinger

26 papers receiving 404 citations

Peers

Countries citing papers authored by Ursula Thyroff‐Friesinger

Since Specialization

Citations

This map shows the geographic impact of Ursula Thyroff‐Friesinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ursula Thyroff‐Friesinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ursula Thyroff‐Friesinger more than expected).

Fields of papers citing papers by Ursula Thyroff‐Friesinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ursula Thyroff‐Friesinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ursula Thyroff‐Friesinger. The network helps show where Ursula Thyroff‐Friesinger may publish in the future.

Co-authorship network of co-authors of Ursula Thyroff‐Friesinger

This figure shows the co-authorship network connecting the top 25 collaborators of Ursula Thyroff‐Friesinger. A scholar is included among the top collaborators of Ursula Thyroff‐Friesinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ursula Thyroff‐Friesinger. Ursula Thyroff‐Friesinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacodynamic equivalence study of two preparations of eye drops, containing dorzolamide in healthy volunteers 2016 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), Ursula Thyroff‐Friesinger, (unknown), Rossen Koytchev	0
2	Randomized equivalence trial: A novel multidose dry powder inhaler and originator device in adult and adolescent asthma 2015 ·Allergy and Asthma Proceedings ·Piotr Kuna, Ursula Thyroff‐Friesinger, (unknown), (unknown)	5
3	Bioequivalence of Sandoz methylphenidate osmotic‐controlled release tablet with Concerta^® (Janssen‐Cilag) 2015 ·Pharmacology Research & Perspectives ·(unknown), (unknown), (unknown), Ursula Thyroff‐Friesinger, (unknown), Werner Weitschies	8
4	Clinical development of two innovative pharmaceutical forms of leuprorelin acetate 2012 ·Therapeutic Advances in Urology ·(unknown), (unknown), Ursula Thyroff‐Friesinger, (unknown), Patricia Gravel	8
5	Clinical development of a new pharmaceutical form of leuprorelin acetate for the treatment of advanced prostate cancer: Pharmacokinetics of a 3-month implant 2012 ·Journal of Geriatric Oncology ·Ursula Thyroff‐Friesinger, (unknown), (unknown)	4
6	Pharmacodynamic equivalence study of two preparations of eye drops containing dorzolamide and timolol in healthy volunteers 2011 ·Arzneimittelforschung ·(unknown), (unknown), (unknown), (unknown), (unknown), Rossen Koytchev, (unknown), (unknown), Ursula Thyroff‐Friesinger	0
7	Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial 2009 ·PubMed ·Fritz Sörgel, Ursula Thyroff‐Friesinger, (unknown), (unknown), Martina Kinzig	29
8	HX575, Recombinant Human Epoetin Alfa, for the Treatment of Chemotherapy-Associated Symptomatic Anaemia in Patients with Solid Tumours 2009 ·Oncology Research and Treatment ·K. Weigang-Köhler, (unknown), Ursula Thyroff‐Friesinger	32
9	A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis 2009 ·European journal of medical research ·Nurlan Dauletbaev, P.-A. Fischer, (unknown), (unknown), (unknown), Ursula Thyroff‐Friesinger, (unknown), Joachim Bargon	38
10	Bioequivalence of HX575 (Recombinant Human Epoetin Alfa) and a Comparator Epoetin Alfa after Multiple Subcutaneous Administrations 2008 ·Pharmacology ·Fritz Sörgel, Ursula Thyroff‐Friesinger, (unknown), (unknown), Martina Kinzig	23
11	Bioequivalence studies with metformin: comparability of reference tablets from different origins 2005 ·International Journal of Clinical Pharmacology and Therapeutics ·(unknown), Ursula Thyroff‐Friesinger, Rossen Koytchev, (unknown), (unknown)	8
12	PK–PD modelling of the effect of cefaclor on four different bacterial strains 2004 ·International Journal of Antimicrobial Agents ·Amparo de la Peña, (unknown), Kenneth H. Rand, (unknown), (unknown), Ursula Thyroff‐Friesinger, Markus Müller, Hartmut Derendorf	21
13	Comparison of peak and trough level monitoring of cyclosporine treatment using two modern cyclosporine preparations 2003 ·Transplantation Proceedings ·Magdalena Durlik, Christoph Rauch, Ursula Thyroff‐Friesinger, (unknown), Leszek Pączek	8
14	Influence of the cytochrome P4502D64 allele on the pharmacokinetics of controlled-release metoprolol 1998 ·European Journal of Clinical Pharmacology* ·Rossen Koytchev, R. G. Alken, (unknown), (unknown), Radka Kaneva, Ursula Thyroff‐Friesinger, (unknown)	24
15	MEFENAMIC ACID BIOEQUIVALENCE ASSESSMENT WITH A NEW STATISTICAL PROCEDURE 1996 ·Pharmacological Research ·Aldo Rescigno, A Marzo, Ursula Thyroff‐Friesinger	4
16	Ibopamine as a Valuable Adjunct and Substitute for Dopamine in Bridging Therapy before Heart Transplantation 1992 ·Cardiology ·(unknown), (unknown), Ursula Thyroff‐Friesinger, (unknown), Dietmar Glogar	4
17	Spectrum and susceptibility of pathogens causing acute uncomplicated lower UTI in females and its correlation to bacteriologic outcome after single dose therapy with fosfomycin trometamol versus ofloxacin/Co-trimoxazole 1992 ·Infection ·Kurt G. Naber, Ursula Thyroff‐Friesinger	10
18	Ibopamine versus Digoxin in the Treatment of Mild Congestive Heart Failure 1990 ·Cardiology ·(unknown), Ursula Thyroff‐Friesinger	11
19	Fosfomycin trometamol versus ofloxacin/Co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: A multicentre study 1990 ·Infection ·Kurt G. Naber, Ursula Thyroff‐Friesinger	38
20	Treatment of Mild Chronic Congestive Heart Failure with Ibopamine, Hydrochlorothiazide, Ibopamine plus Hydrochlorothiazide or Placebo 1990 ·Cardiology ·F. X. Kleber, Ursula Thyroff‐Friesinger	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact